Friday January 28, 10:48 am Eastern Time
Company Press Release
SOURCE: Medarex, Inc.
Medarex Files Registration Statement for Public
Offering
PRINCETON, N.J., Jan. 28 /PRNewswire/ -- Medarex, Inc. (Nasdaq: MEDX - news) today announced that it has filed a
registration statement with the U.S. Securities and Exchange Commission for a public offering of 1.75 million shares of
Common Stock.
(snip)
Friday January 28, 9:22 am Eastern Time
Company Press Release
SOURCE: Abgenix, Inc.
Abgenix Files Common Stock Offering of Up to 2.5
Million Shares
Includes Up to 700,000 Shares to be Sold by Cell Genesys
FREMONT, Calif., Jan. 28 /PRNewswire/ -- Abgenix, Inc. (Nasdaq: ABGX - news) today announced that it has filed a
Registration Statement on Form S-1 with the Securities and Exchange Commission.
The registration statement covers a proposed offering of up to 2,500,000 shares of common stock and includes up to 700,000
shares of common stock to be sold by a selling stockholder, Cell Genesys, Inc. (Nasdaq: CEGE - news). To the extent the
underwriters sell more than 2,500,000 shares of common stock, the underwriters have an option to purchase up to an
additional 375,000 shares, of which 270,000 shares shall be from Abgenix and 105,000 shares shall be from the selling
stockholder, Cell Genesys, Inc.
(snip)
Friday January 28, 8:45 am Eastern Time
Company Press Release
SOURCE: CuraGen Corporation
CuraGen Raises $125 Million from the Sale of
Convertible Debentures
NEW HAVEN, Conn., Jan. 28 /PRNewswire/ -- CuraGen Corporation (Nasdaq: CRGN - news), a genomics based drug
discovery and development company, announced today that it has entered into a purchase agreement providing for the sale to
certain initial purchasers of $125 million aggregate principal amount of convertible subordinated debentures ($150 million if the
over- allotment option is exercised in full).
(snip)
Friday January 28, 8:06 am Eastern Time
Company Press Release
Trimeris Raises Approximately $65 Million Through
Private Placement
DURHAM, N.C.--(BUSINESS WIRE)--Jan. 28, 2000--Trimeris, Inc. (Nasdaq: TRMS - news) today announced that it has
offered and intends to complete a private placement of Trimeris' common stock to new and current shareholders in order to
raise net proceeds of up to approximately $65 million.
In connection with this private placement, the company intends to issue up to 1.75 million shares of common stock. Net
proceeds from the private placement will be used to fund the clinical development of its product candidates, T-20 and T-1249,
to fund increased research and development, to provide working capital and for general corporate purposes.
(snip) |
